Mankind Pharma to acquire Panaceas formulation brands for India and Nepal

Both the entities have entered into definitive agreements for the transaction involving a total consideration of Rs 1,872 crore. Panacea Biotec Pharma Ltd is a wholly-owned subsidiary of Panacea Biotec Mankind Pharma on Monday said it will acquire Panacea Biotec Pharma's formulations brands, for India and Nepal markets, for Rs 1,872 crore. Both the entities have entered into definitive agreements for the transaction involving a total consideration of Rs 1,872 crore. Panacea Biotec Pharma Ltd is a wholly-owned subsidiary of Panacea Biotec. As part of this arrangement, Mankind Pharma is retaining Panacea's sales and marketing team engaged in the particular business. The transaction marks a very historical event which brings about the perfect confluence of both the organisations to complement each other. Panacea has created a niche in the chronic and transplant business and their products are inherently backed up with thorough R&D and are supported by highly complex and distinctive technology," Mankind Pharma Managing Director and Vice-Chairman Rajeev Juneja said in a statement. Through this acquisition Mankind Pharma will be able to explore new therapeutic areas and create visibility in lifestyle, oncology and transplant business, he added. "The sale of domestic formulation brand portfolio is in line with the company's strategic plan to become debt-free and focus on exports of pharmaceutical formulations in the US and other international markets besides the vaccine business in global markets," Panacea Biotec Managing Director Rajesh Jain said in a statement. The divestment will ensure adequate liquidity for these businesses, drive investments in products under development and expand capacities for key vaccine projects to drive future growth in a sustainable manner

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!